Innovent Biologics Deal History & Licensing Activity
Innovent Biologics is a large biotech headquartered in Italy. Over the past three years, Innovent Biologics has been involved in 6 licensing and acquisition transactions, with a primary focus on Antibodies (6 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
5
Active Trials
50
Top Modality
Antibodies
Focus Area
Solid Tumors
Innovent Biologics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Innovent Biologics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| VANFLYTA (quizartinib) | Daiichi Sankyo | Small Molecules | Approved | license | Aug 9, 2026 |
| SP001 (IBI355), Fc-silent anti-CD40L monoclonal antibody | Spero Therapeutics | Antibodies | Phase 1 | license | Jul 14, 2026 |
| 12 oncology programs (ADCs and multi-specific antibodies) | Pfizer | Antibodies | Unknown | collaboration | May 28, 2026 |
| Undisclosed | Eli Lilly | Antibodies | Unknown | collaboration | Feb 8, 2026 |
Innovent Biologics Pipeline Focus
Therapeutic areas and modalities where Innovent Biologics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Innovent Biologics Strategic Signals
Key indicators of Innovent Biologics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Innovent Biologics Clinical Pipeline
Innovent Biologics has 50 active clinical trials across 7 development phases.
1
Phase 4
1
Not Applicable
1
Unknown
19
Phase 1
1
Phase 1/2
16
Phase 2
11
Phase 3
See How Your Asset Matches Innovent Biologics's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Innovent Biologics Licensing & Deal Activity
Innovent Biologics is a large biotech company based in Italy that has been actively engaged in licensing transactions across the biopharma landscape. With 6 deals over the past three years, Innovent Biologics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Innovent Biologics include Solid Tumors (16 deals and trials), Metabolic (11 deals and trials), Oncology (8 deals and trials), and Autoimmune (7 deals and trials). In terms of modality, Innovent Biologics has shown particular interest in antibodies, small molecules, adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Innovent Biologics and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Innovent Biologics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.